Equity Overview
Price & Market Data
Price: $0.65
Daily Change: -$0.0212 / 3.25%
Daily Range: $0.65 - $0.70
Market Cap: $2,935,081
Daily Volume: 4,761
Performance Metrics
1 Week: -5.67%
1 Month: -17.87%
3 Months: -72.64%
6 Months: -90.05%
1 Year: -98.53%
YTD: -78.60%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.